Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
